SynthesisJAMA network open2026
Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review.
Synthesis in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Importance: Federally sponsored cancer clinical trials (FS-CCTs) address research questions often overlooked by industry (eg, pharmaceutical or biotechnology companies), such as treatment combinations, rare cancers, within-class comparisons, and de-escalation strategies. However, drug costs in these trials have not been comprehensively quantified. Federal agencies typically support trial infrastructure but not drugs, necessitating cosponsorship or in-kind donations from pharmaceutical companies. These arrangements often involve complex contractual processes that may delay trial initiation. Quantifying drug-related costs is important for informing policy and optimizing federal support for cancer research. Objective: To estimate the direct purchase costs of drugs in FS-CCTs and examine cost patterns across sponsor types and therapeutic classes. Design, Setting, and Participants: This systematic review included a search of the ClinicalTrials.gov registry using a structured query to identify all US-based cancer treatment trials initiated between January 1, 2017, and December 31, 2023, that involved pharmaceutical or biological interventions and received federal sponsorship. Analyses were conducted between June 1 and September 20, 2025. Exposure: Drug or biological interventions in FS-CCTs. Main Outcomes and Measures: Wholesale acquisition cost-based trial-level total and per-patient drug costs. Between-group comparisons used Mann-Whitney and Kruskal-Wallis tests for 2- and multiple-group comparisons, respectively. Results: A total of 1378 US FS-CCTs with 140 066 participants were included in the analysis. The estimated median trial-level drug costs were $7.58 million (IQR, $2.11-$19.88 million), with substantially higher median costs for phase 3 trials ($58.92 million [IQR, $12.25-$127.17 million]) vs early phase trials ($6.90 million [IQR, $2.01-$17.70 million]) (P < .001) and for immunotherapies ($9.25 million [IQR, $3.12-$23.22 million]), targeted therapies ($6.60 million [IQR, $2.22-$18.06 million]), and combined immunotherapy and targeted therapy ($15.08 million [IQR, $6.30-$34.83 million]) compared with chemotherapy ($0.43 million [IQR, $0.11-$2.87 million]) (P < .001). Experimental agents accounted for approximately 80% of total drug costs. The median per-patient drug costs were higher in trials that were solely federally funded ($196 764 [IQR, $83 516-$414 514]) vs cosponsored trials ($149 879 [IQR, $35 329-$390 142]) (P < .001). Among 221 comparative phases 2 to 3 trials, the median experimental arm costs ($12.91 million [IQR, $3.37-$46.96 million]) were 5-fold higher than in control arms ($2.05 million [IQR, $0.16-$11.31 million]). Conclusions and Relevance: In this systematic review of FS-CCTs, drug costs were substantial, particularly in late-stage trials and those examining immunotherapies and targeted agents. High costs routinely required federally sponsored groups to seek industry support, which may have limited independence and constrained new treatment discovery. Policy innovations are needed to reduce trial drug cost burden and enable FS-CCT researchers to conduct scientifically and clinically relevant trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.